Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target Activated CIK for Advanced Colorectal Cancer
NCT03524274Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Apr 2018
- Primary completion
- May 2020
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of activated CIK cells + anti-CD3-MUC1 bispecific antibody in colorectal cancer (CRC), sponsored by Fuda Cancer Hospital. Planned start Apr 2018; status: withdrawn.
02
Drugs
activated CIK cells + anti-CD3-MUC1 bispecific antibody
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03524274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524274.